Over 100 Florida Auctions End Today - Bid Now
Over 1450 Total Lots Up For Auction at Six Locations - Over 120 New Jersey Auctions End Tomorrow 10/19 - Bid Now, MN 10/20, NY 10/22, NY 10/25, TX 10/28, CA 10/29

Molecular Targeting Technologies to supply n.c.a. 177Lu to Isotopia Molecular Imaging

par John R. Fischer, Senior Reporter | March 29, 2021
Molecular Imaging
Molecular Targeting Technologies will supply Isotopia Molecular Imaging with no-carrier-added 177Lu to support development of its radiotherapeutic solutions
Molecular Targeting Technologies Inc. (MTTI), a biopharmaceutical company, will supply Isotopia Molecular Imaging with no-carrier-added 177Lu (n.c.a. 177Lu ).

The supply will support clinical development of MTTI's products, 177Lu-EBTATE, for targeting somatostatin receptors type 2 in a variety of neuroendocrine tumors (NETs); and 177Lu-EBRGD, for integrin expressing cancers in glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC).

"We've secured a timely and sustainable supply of a key therapeutic ingredient needed for the development and launch of our lead asset 177Lu-EBTATE and other EB platform technologies,” said Dr. Chris Pak, president and CEO of MTTI, in a statement.

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

177Lu is designed to precisely destroy tumors when bound to disease-specific, targeting therapeutics and can penetrate soft tissue at a maximum of one millimeter from its binding site. It is covered by the NIH's Evans Blue Platform technology patents. The EB helps boost 177Lu's half-life of 6.7 days and delivers a high dosage to the targeted tumor.

Isotopia uses a unique, stable GMP method to produce a highly pure form of 177Lu. n.c.a. and eliminates cost-intensive clinical waste management.

MTTI plans to sell it through an exclusive NIH worldwide license.

"Our strategy is to be a partner to every leading pharmaceutical company developing Lu-177 n.c.a.-based products, supporting them from clinical trials through commercial sale. We are committed to produce 52 weeks per year, ensuring supply through long-term contracts,” said Isotopia's CEO Dr. Eli Shalom.

You Must Be Logged In To Post A Comment